Search Results for: "Clinic Roundup"
-
Clinic Roundup
Thus, IQP-0410 can be dosed once per day, and possesses a highly positive safety profile, which suggests it will be amenable for use in women of child-bearing years, the company saidBioWorld Today | Tuesday, February 10, 2009 -
Clinic Roundup
The trial met its primary endpoints and demonstrated a favorable safety profile compared with gabapentinBioWorld Today | Wednesday, January 28, 2009 -
Clinic Roundup
Data from the trial will be used to design larger studies to provide safety profile for approval purposesBioWorld Today | Monday, January 26, 2009 -
Clinic Roundup
Those results showed the product candidate to have an excellent safety profile and suggested that it may be suitable for administration on a once-monthly basisBioWorld Today | Friday, January 16, 2009 -
Clinic Roundup
Algeta ASA, of Oslo, Norway, said results of its BC1-04 Phase II study evaluating Alpharadin (radium-223) as a treatment for bone metastases in patients with hormone-refractory prostate cancer showed strong evidence that Alpharadin can prolong patient survival times, improve quality of life and offer a placebo-like safety profileBioWorld Today | Thursday, January 15, 2009 -
Clinic Roundup
At all concentrations, for both the two-day and three-day treatments, the PEP005 Gel demonstrated a favorable safety profile and was well toleratedBioWorld Today | Friday, January 9, 2009 -
Clinic Roundup
Theratechnologies Inc., of Montreal, reported 52-week results of its confirmatory Phase III trial, evaluating the long-term safety profile of its lead compound, tesamorelin, in patients with HIV-associated lipodystrophy...The results showed are consistent with the safety profile observed in the first Phase III trialBioWorld Today | Tuesday, December 16, 2008 -
Clinic Roundup
Data from the placebo-controlled, single-ascending dose trial of a single intravenous administration of NU206 in 32 healthy male volunteers showed that the compound had a favorable safety profile, no serious adverse events were observed and pharmacokinetics were predictableBioWorld Today | Thursday, December 11, 2008 -
Clinic Roundup
The Phase I portion will assess the safety profile and test pharmacokinetic and pharmacodynamic activities, while the Phase II component is designed to test the clinical benefitsBioWorld Today | Tuesday, December 2, 2008 -
Clinic Roundup
Bioniche Life Sciences Inc., of Belleville, Ontario, presented data showing its Mycobacterial Cell Wall-DNA Complex (Urocidin) with an excellent safety profile in older patients...The safety profile of Avastin was consistent with previous experience, and no new safety signals were observedBioWorld Today | Tuesday, November 25, 2008 -
Clinic Roundup
The robust safety profile was maintained at six months with no evidence of adverse events or immunologic reactionsBioWorld Today | Thursday, November 20, 2008 -
Clinic Roundup
Avexa Ltd., of Melbourne, Australia, said 48-week data from a Phase IIb trial showed that apricitabine provided significant and durable antiviral activity over the treatment period in treatment-experienced HIV patients, with a favorable safety profile and no evidence of resistance developmentBioWorld Today | Friday, November 14, 2008 -
Clinic Roundup
and continued to have a strong safety profile, confirming results from previous studiesBioWorld Today | Wednesday, November 12, 2008 -
Clinic Roundup
Bavarian Nordic A/S, of Kvistgard, Denmark, completed a safety report from a large Phase II study with Imvamune in HIV-infected subjects, which confirmed an excellent safety profile for the smallpox vaccineBioWorld Today | Friday, November 7, 2008 -
Clinic Roundup
The presentation reported the absence of serious, dose-limiting adverse events in the study and concluded that the data demonstrate an acceptable safety profile for multiple subcutaneous doses of MEDI-528BioWorld Today | Thursday, October 30, 2008 -
Clinic Roundup
In addition, bevirimat's safety profile was comparable to earlier studies where it had been indistinguishable from placeboBioWorld Today | Wednesday, October 29, 2008 -
Clinic Roundup
HUYA Bioscience International LLC, of San Diego, and Chipscreen Biosciences Ltd., of Shenzhen, China, said a Phase I trial of Chidamide (HBI-8000) demonstrated best-in-class pharmacokinetics, biomarker and safety profiles, as well as activity against T-lymphoma and other tumor types...Based on its mechanism of action and safety profile in AD patients, the company said, HF0220 may have synergistic effects in combination with currently marketed anti-dementia drugsBioWorld Today | Friday, October 24, 2008 -
Clinic Roundup
Positive results for other study endpoints, including increased median progression-free survival and tumor stabilization, were shown, and the drug's safety profile was favorableBioWorld Today | Tuesday, October 21, 2008 -
Clinic Roundup
Kamada Ltd., of Ness Ziona, Israel, said data from its Phase II study evaluating inhaled alpha-1 antitrypsin delivered via an investigational eFlow nebulizer system (PARI Pharma GmbH) in the treatment of cystic fibrosis, demonstrated that the product has an excellent safety profile and showed promising signs of efficacy, as indicated by a reduction in lung inflammationBioWorld Today | Tuesday, October 14, 2008 -
Clinic Roundup
The first trials comprise ascending dose studies to determine the maximum tolerated dose and to assess the pharmacokinetics and overall safety profile of SB1518BioWorld Today | Friday, September 19, 2008
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.